Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 17/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396278 | 0.95 | CACNA1B (0.44) | CACNA1BNR1I2CYP3A4USP2ALDH1A1 | |
| SCHEMBL3765000 | 0.86 | CACNA1B (0.48) | CACNA1BNR1I2CYP3A4GAAHPGD | |
| SCHEMBL4389619 | 0.86 | CACNA1B (0.49) | CACNA1BNR1I2CYP3A4USP2ALDH1A1 | |
| SCHEMBL3763660 | 0.85 | CACNA1B (0.47) | CACNA1BNR1I2CYP3A4GAAHPGD | |
| SCHEMBL4398026 | 0.85 | LMNA (0.46) | CACNA1BNR1I2CYP3A4USP2ALDH1A1 | |
| SCHEMBL8236293 | 0.83 | CACNA1B (0.51) | CACNA1BNR1I2CYP3A4USP2ALDH1A1 | |
| SCHEMBL13002406 | 0.80 | CACNA1B (0.51) | CACNA1BNR1I2CYP3A4GAAHPGD | |
| SCHEMBL3485159 | 0.80 | CACNA1B (0.50) | CACNA1BNR1I2CYP3A4GAAHPGD | |
| SCHEMBL3485614 | 0.79 | GAA (0.50) | CACNA1BNR1I2CYP3A4USP2ALDH1A1 | |
| SCHEMBL3762464 | 0.79 | CACNA1B (0.46) | CACNA1BNR1I2CYP3A4GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | claimed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | claimed |
| WO-2007118854-A1 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | claimed |
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937181-B2 | Benzenesulfonamide compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | disclosed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | disclosed |
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | PURDUE PHARMA L.P. | 2009-12-10 | — | — | US | disclosed |
| WO-2007118854-A1 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118854-A1 | BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306136-A1 | Benzenesulfonamide Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1B | CACNA1B 3/4885NR1I2 1980/4885CYP3A4 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.